Severe peripheral neuropathy following carfilzomib, rituximab, and dexamethasone for initial treatment of Waldenström’s macroglobulinemia

Annals of Hematology

Volumn 95, Issue 2, 2016, Pages 347-348

  Alfaraj, Walla A ^a   Cachia, David ^a   Tummala, Sudhakar ^a   Thomas, Sheeba K ^a   Manasanch, Elisabet E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; BENCE JONES PROTEIN; BENDAMUSTINE; CARFILZOMIB; CD5 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CRYOGLOBULIN; CYANOCOBALAMIN; DEXAMETHASONE; GABAPENTIN; HYDROMORPHONE; IMMUNOGLOBULIN M; MYELIN ASSOCIATED GLYCOPROTEIN; MYELOID DIFFERENTIATION FACTOR 88; PLASMA PROTEIN; RITUXIMAB; VITAMIN D; ANTINEOPLASTIC AGENT; OLIGOPEPTIDE;

ABDOMINAL FAT ASPIRATION BIOPSY; ADULT; ANEMIA; B CELL LYMPHOMA; BIOPSY; BONE MARROW BIOPSY; CANCER STAGING; CASE REPORT; CERVICAL LYMPH NODE; CONSERVATIVE TREATMENT; DISEASE SEVERITY; DRUG EFFICACY; DRUG SUBSTITUTION; ELECTROMYOGRAPHY; ELECTROPHORESIS; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; INFECTION COMPLICATION; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LEG PAIN; LETTER; LIGHT CHAIN; LYMPHADENOPATHY; MALE; MANAGED CARE; MEDICAL HISTORY; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NERVE CONDUCTION; NIGHT SWEAT; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; SENSORIMOTOR NEUROPATHY; SPINAL CORD STIMULATOR; SPINE RADIOGRAPHY; THORACOLUMBAR SPINE; TREATMENT DURATION; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA; WALKING AID; CHEMICALLY INDUCED; PERIPHERAL NERVOUS SYSTEM DISEASES; SEVERITY OF ILLNESS INDEX; WALDENSTROM MACROGLOBULINEMIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PERIPHERAL NERVOUS SYSTEM DISEASES; RITUXIMAB; SEVERITY OF ILLNESS INDEX; WALDENSTROM MACROGLOBULINEMIA;

EID: 84955204864     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-015-2516-7     Document Type: Letter

References (9)

1. Treon SP (2015) How I treat Waldenstrom macroglobulinemia. Blood. doi:10.1182/blood-2015-01-553974
2. Dimopoulos MA, Garcia-Sanz R, Gavriatopoulou M, Morel P, Kyrtsonis MC, Michalis E, Kartasis Z, Leleu X, Palladini G, Tedeschi A, Gika D, Merlini G, Kastritis E, Sonneveld P (2013) Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood 122(19):3276–3282. doi:10.1182/blood-2013-05-503862
3. Treon SP, Ioakimidis L, Soumerai JD, Patterson CJ, Sheehy P, Nelson M, Willen M, Matous J, Mattern J 2nd, Diener JG, Keogh GP, Myers TJ, Boral A, Birner A, Esseltine DL, Ghobrial IM (2009) Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05–180. J Clin Oncol Off J Am Soc Clin Oncol 27(23):3830–3835. doi:10.1200/JCO.2008.20.4677
4. Ghobrial IM, Xie W, Padmanabhan S, Badros A, Rourke M, Leduc R, Chuma S, Kunsman J, Warren D, Poon T, Harris B, Sam A, Anderson KC, Richardson PG, Treon SP, Weller E, Matous J (2010) Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom macroglobulinemia. American Journal of Hematology 85(9):670–674. doi:10.1002/ajh.21788
5. Treon SP, Tripsas CK, Meid K, Kanan S, Sheehy P, Chuma S, Xu L, Cao Y, Yang G, Liu X, Patterson CJ, Warren D, Hunter ZR, Turnbull B, Ghobrial IM, Castillo JJ (2014) Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom’s macroglobulinemia. Blood 124(4):503–510. doi:10.1182/blood-2014-03-566273
6. CTCAE 4.0 criteria (2015) http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed 4/11/2015
7. Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J, Crowley J, Ocio EM, Garcia-Sanz R, Treon SP, Leblond V, Kyle RA, Barlogie B, Merlini G (2009) International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 113(18):4163–4170. doi:10.1182/blood-2008-08-174961
8. Noronha V, Fynan TM, Duffy T (2006) Flare in neuropathy following rituximab therapy for Waldenstrom’s macroglobulinemia. J Clin Oncol Off J Am Soc Clin Oncol 24(1):e3. doi:10.1200/JCO.2005.04.6474
9. Gironi M, Saresella M, Ceresa L, Calvo M, Ferrante P, Merli F, Nemni R (2006) Clinical and immunological worsening in a patient affected with Waldenstrom macroglobulinemia and anti-mag neuropathy after treatment with rituximab. Haematologica 91(6 Suppl):ECR17